NCT04903093 - A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 4, 2021

Primary Completion Date

October 26, 2021

Study Completion Date

October 26, 2021

Conditions

Healthy Volunteers

Interventions

DRUG

Abrocitinib tablet

Single dose of abrocitinib 200 mg tablet will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F1

Single dose of abrocitinib 200 mg oral suspension formulation 1 will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F2

Single dose of abrocitinib 200 mg oral suspension formulation 2 will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F3

Single dose of abrocitinib 200 mg oral suspension formulation 3 will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F4

Single dose of abrocitinib 200 mg oral suspension formulation 4 will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F5

Single dose of abrocitinib 200 mg oral suspension formulation 5 will be administered after an overnight fast of at least 10 hours.

DRUG

Abrocitinib Suspension F6

Single dose of abrocitinib 200 mg oral suspension formulation 6 will be administered after an overnight fast of at least 10 hours.

DRUG

Famotidine

Single dose of famotidine 40 mg tablet administered 2 hours prior to abrocitinib formulations under fasted conditions.

Trial Locations (1)

New Haven Clinical Research Unit, New Haven